Compare MUSA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUSA | IBRX |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | 16900 | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 8.4B |
| IPO Year | 2013 | 2015 |
| Metric | MUSA | IBRX |
|---|---|---|
| Price | $504.48 | $7.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $458.43 | $12.57 |
| AVG Volume (30 Days) | 343.9K | ★ 24.4M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 24.10 | N/A |
| Revenue | ★ $21,529,400,000.00 | $113,288,000.00 |
| Revenue This Year | $17.24 | $88.59 |
| Revenue Next Year | $3.49 | $131.15 |
| P/E Ratio | $20.43 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $345.23 | $1.83 |
| 52 Week High | $523.09 | $12.43 |
| Indicator | MUSA | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 74.06 | 45.27 |
| Support Level | $357.92 | $2.25 |
| Resistance Level | N/A | $8.28 |
| Average True Range (ATR) | 15.39 | 0.89 |
| MACD | 4.43 | -0.25 |
| Stochastic Oscillator | 99.99 | 28.17 |
Murphy USA Inc is mainly engaged in the marketing of retail motor fuel products and convenience merchandise through a network of several retail stores in the Southwest, Southeast, Midwest, and Northeast United States. The majority of Murphy USA's stores are located in proximity to Walmart Supercenters, but it also operates standalone stores that market gasoline and other products under the Murphy USA, Murphy Express, and QuickChek brands. In addition, the company also markets fuel to unbranded wholesale customers through a mixture of company-owned and third-party product distribution terminals and pipeline positions. The firm generates maximum revenue through retail sales of petroleum products, and the rest from merchandise sales and wholesale of petroleum products.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.